VAX 161
Alternative Names: Influenza A virus H5N1 vaccine – VaxInnate; VAX-161C; VAX161; VAX161B; VAX161B [STF2.HA5 H5N1]Latest Information Update: 12 Sep 2017
At a glance
- Originator VaxInnate
- Class Antivirals; Influenza A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus H5N1 subtype
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention, In volunteers) in USA (IM, Injection)
- 01 Dec 2013 VaxInnate completes a phase I trial in Influenza-A virus H5N1 subtype (in volunteers, prevention) in USA (NCT01658800)
- 30 Nov 2013 VaxInnate completes a phase I trial in Influenza-A virus H5N1 subtype (in volunteers, prevention) in USA (NCT01560793)